HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Targeting of saporin to Hodgkin's lymphoma cells by anti-CD30 and anti-CD25 bispecific antibodies.

Abstract
CD25 and CD30 represent suitable target molecules for bispecific antibody (bimAb)-driven toxin delivery to lymphoid tumour cells. We describe two new anti-CD30/anti-saporin bimAbs (termed CD30 x sap1 and CD30 x sap2), produced by hybrid hybridomas, which react against non-cross-reactive epitopes of the saporin molecule, and compared their effect with a bimAb reacting with saporin and with CD25 (CD25 x sap1). In a protein synthesis inhibition assay these bimAbs were able to enhance saporin toxicity (IC50 = 8.5 x 10(-9) M in the absence of mAbs) with a similar activity: in the presence of 10(-9) M CD30 x sap1 bimAb the IC50 was 2.75 x 10(-11) M, whereas with CD30 x sap2 bimAb the IC50 was 6.5 x 10(-11) M and CD25 x sap1 bimAb displayed an IC50 of 3 x 10(-11) M (as saporin). The combined use of the two anti-CD30 bimAbs further increased cytotoxicity by 100-fold, resulting in an IC50 of 1.9 x 10(-13) M. A slightly less efficient improvement was obtained by combining the CD25 x sap1 bimAb with the CD30 x sap2 bimAb directed against a different toxin epitope (saporin IC50 to 7 x 10(-13) M). In contrast, no synergistic effect was observed using the combination of the anti-CD25 bimAb with the anti-CD30 bimAb reacting with the same epitope of saporin (IC50 = 4.5 x 10(-11) M). Analysis of FITC-saporin binding to L540 cells by flow cytometry demonstrated that the appropriate combinations of the two anti-CD30/anti-saporin bimAbs or of the anti-CD30/anti-saporin and anti-CD25/anti-saporin bimAbs had a cooperative effect on the binding of the ribosome-inactivating protein (RIP) to the cells, when compared with single bimAbs.
AuthorsS Sforzini, D de Totero, A Gaggero, R Ippoliti, M J Glennie, S Canevari, H Stein, S Ferrini
JournalBritish journal of haematology (Br J Haematol) Vol. 102 Issue 4 Pg. 1061-8 (Sep 1998) ISSN: 0007-1048 [Print] England
PMID9734659 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Bispecific
  • Antigens, Neoplasm
  • Antineoplastic Agents, Phytogenic
  • Immunotoxins
  • Ki-1 Antigen
  • Neoplasm Proteins
  • Plant Proteins
  • Receptors, Interleukin-2
  • Ribosome Inactivating Proteins, Type 1
  • N-Glycosyl Hydrolases
  • Saporins
Topics
  • Antibodies, Bispecific (biosynthesis, immunology)
  • Antigens, Neoplasm (immunology)
  • Antineoplastic Agents, Phytogenic (immunology, pharmacokinetics, pharmacology)
  • Cell Death (drug effects)
  • Dose-Response Relationship, Drug
  • Hodgkin Disease (immunology, metabolism)
  • Humans
  • Hybridomas (immunology)
  • Immunotoxins (pharmacokinetics)
  • Ki-1 Antigen (immunology)
  • N-Glycosyl Hydrolases
  • Neoplasm Proteins (biosynthesis)
  • Plant Proteins (immunology, pharmacokinetics, pharmacology)
  • Receptors, Interleukin-2 (immunology)
  • Ribosome Inactivating Proteins, Type 1
  • Saporins
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: